Cabozantinib (20mg)
Original price was: ₹6,807.00.₹2,500.00Current price is: ₹2,500.00.
 Prescription Required
Salt : Temozolomide
Manufacturer : RPG Life Sciences Ltd
Packing : 30 tablets in 1 bottle
1. Product Introduction
Temotide 250mg Capsule is an anti-cancer (chemotherapy) medication that contains Temozolomide as its active ingredient. It is an oral alkylating agent specifically designed to treat certain types of brain tumors. Temozolomide belongs to a class of medicines known as imidazotetrazine derivatives, and it works by damaging the DNA of cancer cells, thereby preventing their growth and multiplication.
Temotide is widely used as part of a standard treatment protocol for brain cancers such as glioblastoma multiforme and anaplastic astrocytoma. It is often used alone or in combination with radiotherapy, depending on the clinical condition of the patient. The capsule form offers a convenient, at-home treatment option, especially for patients undergoing long-term therapy.
This medication should always be taken under the guidance and prescription of an oncologist. Dosage and duration vary depending on the type and stage of the cancer, as well as the patient’s response to the treatment.
2. Uses of This Medicine
Temotide 250mg Capsule is primarily used in the treatment of the following conditions:
-
Glioblastoma Multiforme (GBM): A fast-growing and aggressive type of brain tumor. Temozolomide is used alongside radiotherapy and continued as maintenance therapy to control tumor growth.
-
Anaplastic Astrocytoma: A type of high-grade glioma (brain tumor) that affects the supportive tissues of the brain. Temozolomide helps in reducing tumor size and slowing progression.
-
Off-Label Uses: In some cases, oncologists may prescribe Temozolomide for other malignancies such as metastatic melanoma or secondary brain tumors, depending on the patient’s condition and the sensitivity of the tumor to the drug.
The treatment plan may involve daily or cyclical dosing schedules, typically on a 28-day cycle, depending on whether the patient is in the radiotherapy phase or maintenance phase.
3. Benefits of This Medicine
-
Effective Against Brain Tumors: Temotide offers targeted action against aggressive and high-grade brain tumors, helping in reducing their size and spread.
-
Improves Survival Rates: When combined with radiotherapy, Temozolomide has shown significant improvement in survival rates, especially in glioblastoma patients.
-
Oral Chemotherapy: Being available in capsule form makes it easy to administer, avoiding the need for intravenous infusions. This is particularly convenient for long-term cancer care.
-
Crosses Blood-Brain Barrier: One of the major advantages of Temozolomide is its ability to cross the blood-brain barrier effectively, making it suitable for treating brain tumors where many drugs cannot reach.
-
Better Quality of Life: By controlling tumor progression and symptoms such as headaches, seizures, and neurological issues, Temotide can improve the quality of life for patients.
-
Used in Maintenance Therapy: After completion of initial radiotherapy, Temozolomide is used as maintenance therapy to prolong the effects of treatment and delay recurrence.
4. Side Effects
Like most chemotherapy drugs, Temotide 250mg Capsule can cause certain side effects, which may vary from person to person. Patients are advised to take it strictly under medical supervision and report any unusual symptoms promptly.
Common Side Effects:
-
Nausea and vomiting
-
Fatigue or tiredness
-
Loss of appetite
-
Hair thinning or hair loss
-
Constipation
-
Headache
-
Drowsiness or sleep disturbances
Serious Side Effects:
-
Low blood cell counts (anemia, leukopenia, thrombocytopenia)
-
Severe infections due to weakened immune system
-
Liver function abnormalities
-
Allergic reactions (rash, itching, swelling)
-
Unusual bleeding or bruising
-
Neurological issues (confusion, seizures)
Routine blood tests are essential to monitor blood counts and liver function throughout the treatment course.
5. Frequently Asked Questions (FAQ)
Q1. What is Temotide 250mg Capsule used for?
Temotide is used to treat certain types of brain tumors, including glioblastoma multiforme and anaplastic astrocytoma. It works by interfering with the DNA in cancer cells, thereby stopping their growth.
Q2. How should I take Temotide 250mg Capsule?
Take this medicine exactly as prescribed by your doctor. Swallow the capsule whole with water on an empty stomach, preferably at the same time each day. Do not crush or open the capsule.
Q3. What should I do if I miss a dose?
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed one. Do not take two doses at the same time to make up for a missed dose.
Q4. Can I take this medicine during pregnancy?
No. Temozolomide can harm an unborn baby. It is not recommended during pregnancy or while breastfeeding. Use effective contraception during and for at least 6 months after treatment.
Q5. Are there any dietary restrictions while taking Temotide?
There are no strict dietary restrictions, but it is advised to take the medication on an empty stomach. Maintain a healthy diet to support your immune system and general health.
Reference
- ^ “Cabozantinib Use During Pregnancy”. Drugs.com. 30 March 2020. Retrieved 23 September 2020.
- ^ “Cabometyx (Ipsen Pty Ltd)”. Therapeutic Goods Administration (TGA). 13 January 2023. Retrieved 9 April 2023.
- ^ “Cabometyx cabozantinib (as (S)-malate) 20 mg film-coated tablet bottle (283800)”. Therapeutic Goods Administration (TGA). 27 May 2022. Retrieved 9 April 2023.
- ^ “AusPAR: Cabozantinib”. Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ “Summary Basis of Decision (SBD) for Cabometyx”. Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ “Drug and medical device highlights 2018: Helping you maintain and improve your health”. Health Canada. 14 October 2020. Retrieved 17 April 2024.
- ^ Jump up to:a b c d e f g h i j “Cabometyx 20mg, 40mg, 60mg – Summary of Product Characteristics (SmPC)”. (emc). 7 October 2022. Retrieved 9 April 2023.
- ^ Jump up to:a b c d e “Cometriq 20 & 80 mg hard capsules – Summary of Product Characteristics (SmPC)”. (emc). 6 October 2022. Retrieved 9 April 2023.
- ^ Jump up to:a b c d e f g h i “Cabometyx- cabozantinib tablet”. DailyMed. 21 July 2020. Retrieved 23 September 2020.
- ^ Jump up to:a b c d e f “Cometriq- cabozantinib kit Cometriq- cabozantinib capsule”. DailyMed. 11 February 2020. Retrieved 23 September 2020.
- ^ Jump up to:a b c “Cometriq EPAR”. European Medicines Agency (EMA). 17 September 2018. Retrieved 23 September 2020.
- ^ Jump up to:a b c “Cabometyx EPAR”. European Medicines Agency (EMA). 17 September 2018. Retrieved 23 September 2020.
- ^ Jump up to:a b “FDA approves Cometriq to treat rare type of thyroid cancer” (Press release). U.S. Food and Drug Administration (FDA). 29 November 2012. Archived from the original on 7 July 2014.
- ^ Jump up to:a b “Drug Approval Package: Cometriq (cabozantinib) Capsules NDA #203756”. U.S. Food and Drug Administration (FDA). Retrieved 23 September 2020.
- ^ Jump up to:a b “Cabozantinib (Cabometyx)”. U.S. Food and Drug Administration (FDA). 25 April 2016. Retrieved 23 September 2020.
- ^ Jump up to:a b “Cabometyx (cabozantinib) Tablets”. U.S. Food and Drug Administration (FDA). 12 January 2018. Retrieved 23 September 2020.
- ^ Jump up to:a b c “FDA grants regular approval to Cabometyx for first-line treatment of a”. U.S. Food and Drug Administration (FDA). 19 December 2017. Retrieved 23 September 2020.Â
 This article incorporates text from this source, which is in the public domain. - ^ “FDA approves cabozantinib for differentiated thyroid cancer”. U.S. Food and Drug Administration (FDA). 22 September 2021. Retrieved 22 September 2021.  This article incorporates text from this source, which is in the public domain.
- ^ “FDA Roundup: March 28, 2025”. U.S. Food and Drug Administration (FDA) (Press release). 28 March 2025. Retrieved 28 March 2025.  This article incorporates text from this source, which is in the public domain.
- ^ Jump up to:a b “FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET”. U.S. Food and Drug Administration (FDA). 26 March 2025. Retrieved 28 March 2025.  This article incorporates text from this source, which is in the public domain.
- ^ Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. (December 2011). “Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth”. Molecular Cancer Therapeutics. 10 (12): 2298–2308. doi:10.1158/1535-7163.MCT-11-0264. PMID 21926191. S2CID 16709393.
- ^ “Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US”. ICER. Retrieved 6 February 2025.
- ^ “Cabozantinib Orphan Drug Designations and Approvals”. U.S. Food and Drug Administration (FDA). 29 November 2010. Retrieved 11 November 2020.
- ^ “Search Orphan Drug Designations and Approvals”. U.S. Food and Drug Administration (FDA). 2 March 2017. Retrieved 11 November 2020.
- ^ “Thyroid cancer drug cabozantinib prolongs PFS”. Archived from the original on 2 April 2012. Retrieved 24 October 2011.
- ^ Garde D (1 March 2016). “Ipsen bets up to $855M on Exelixis’ once-failed cancer drug”. FierceBiotech.
- ^ “FDA approves cabozantinib for hepatocellular carcinoma”. U.S. Food and Drug Administration (FDA). 14 January 2019. Retrieved 23 September 2020.  This article incorporates text from this source, which is in the public domain.
- ^ “Search of: cabozantinib | Recruiting, Active, not recruiting, Enrolling by invitation Studies – List Results – ClinicalTrials.gov”. clinicaltrials.gov. Retrieved 9 August 2021.
- ^ Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, et al. (January 2021). “Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial”. Nature Medicine. 27 (1): 165–173. doi:10.1038/s41591-020-01193-6. PMC 8275010. PMID 33442015.                                                                                                   Â
Disclaimer
Online Medicos primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Online Medicos Our mission is to support, not replace, the doctor-patient relationship
Shipping Policy
We ship across India. Note – this is subject to change as per Company Wishes. Packages will be shipped in 24 working hours. we are closed on Sundays and will reach you in the next 2-4 days post shipping. We give the estimated time of delivery on the shipping page. However, these are indicative and depend on our shipping partner.
Delivery
The delivery times are subject to location, distance, and our logistics partners. We are not liable for any delays in delivery by the courier company/postal authorities but will help you track down a package through our partner courier services.
Your purchases may reach you from various locations in more than one package. But rest assured, you will be charged one delivery fee for the entire order. As soon as your package ships, we will email you your package tracking information.
We are bound in coverage by their reach even though we use some of India’s largest logistics companies for shipping. In case your address is in a location not served by them we would contact you to find an alternative solution to make your products reach you.
Reviews
There are no reviews yet.